Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

被引:30
作者
Jorga, KM [1 ]
Fotteler, B
Heizmann, P
Zürcher, G
机构
[1] F Hoffmann La Roche & Co Ltd, Clin Pharmacol, CH-4070 Basel, Switzerland
[2] F Hoffmann La Roche & Co Ltd, Dept Res & Dev, CH-4002 Basel, Switzerland
关键词
tolcapone; Parkinson's disease; COMT inhibition;
D O I
10.1007/s002280050490
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To evaluate fully the pharmacokinetics and pharmacodynamics of tolcapone, a never inhibitor of catechol-O-methyltransferase (COMT), after oral and intravenous administration. Methods: Sixteen healthy male volunteers were given tolcapone in single doses of 200 mg orally and 50 mg intravenously, separated by a washout period of 7 days or more, in a single-center, open-label, randomized, cross-over study. Pharmacokinetic parameters were calculated using both compartmental and non-compartmental methods; pharmacodynamics were evaluated from erythrocyte COMT activity. Results: After an initial lag time of 0.5 h, tolcapone was rapidly absorbed (peak plasma concentrations were reached within approximately 2 h) following either zero- or first-order absorption kinetics. The absolute bioavailability of an oral dose was approximately 60%. The volume of distribution was approximately 9 l, and the total clearance was approximately 7 l.h(-1), resulting in a mean plasma half-life of 1.8 h. The degree of erythrocyte COMT inhibition was closely related to tolcapone plasma concentration; a rebound in COMT activity was observed after tolcapone withdrawal. Both oral and intravenous tolcapone were well tolerated. Discussion: Because of its relatively low systemic clearance, tolcapone exhibits only a small degree of first-pass metabolism and a relatively good oral bioavailability, which explains the higher plasma concentrations and stronger COMT inhibition observed with tolcapone compared with entacapone, another COMT inhibitor. The pharmacokinetic and pharmacodynamic profile of tolcapone obtained in this study underlines the potential of the agent to be used as an adjunct to levodopa in the treatment of Parkinson's disease.
引用
收藏
页码:443 / 447
页数:5
相关论文
共 21 条
[1]   Catechol-O-methyltransferase inhibition with tolcapone reduces the ''wearing off'' phenomenon and levodopa requirements in fluctuating parkinsonian patients [J].
Baas, H ;
Beiske, AG ;
Ghika, J ;
Jackson, M ;
Oertel, WH ;
Poewe, W ;
Ransmayr, G ;
Auff, E ;
Volc, D ;
Dupont, E ;
Mikkelsen, B ;
Wermuth, L ;
WommPetersen, J ;
Benecke, R ;
Eichhom, T ;
Kolbe, H ;
Oertel, W ;
Schimrigk, K ;
Olsson, JE ;
Palhagen, S ;
Burgunder, JM ;
Ghika, A ;
Regli, F ;
Steck, A ;
Medcalf, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (04) :421-428
[2]   INDUCTION OF AROMATIC-L-AMINO ACID DECARBOXYLASE BY DECARBOXYLASE INHIBITORS IN IDIOPATHIC PARKINSONISM [J].
BOOMSMA, F ;
MEERWALDT, JD ;
TVELD, AJMI ;
HOVESTADT, A ;
SCHALEKAMP, MADH .
ANNALS OF NEUROLOGY, 1989, 25 (06) :624-628
[3]  
CALNE DB, 1993, NEW ENGL J MED, V329, P1021
[4]  
DAPRADA M, 1995, NEUROLOGY, V45, pA252
[5]   Multiple dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects [J].
Dingemanse, J ;
Jorga, K ;
Zurcher, G ;
Fotteler, B ;
Sedek, G ;
Nielsen, T ;
vanBrummelen, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (1-2) :47-55
[6]   INTEGRATED PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE DURING FIRST ADMINISTRATION TO HUMANS [J].
DINGEMANSE, J ;
JORGA, KM ;
SCHMITT, M ;
GIESCHKE, R ;
FOTTELER, B ;
ZURCHER, G ;
DAPRADA, M ;
VANBRUMMELEN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (05) :508-517
[7]   PHARMACOKINETIC-PHARMACODYNAMIC INTERACTION BETWEEN THE COMT INHIBITOR TOLCAPONE AND SINGLE-DOSE LEVODOPA [J].
DINGEMANSE, J ;
JORGA, K ;
ZURCHER, G ;
SCHMITT, M ;
SEDEK, G ;
DAPRADA, M ;
VANBRUMMELEN, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) :253-262
[8]  
Fahn S., 1989, DRUGS TREATMENT PARK, P385, DOI [10.1007/978-3-642-73899-9_14, DOI 10.1007/978-3-642-73899-9_14]
[9]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[10]  
HOLFORD NHG, 1981, CRC CR REV BIOM ENG, V5, P273